Another IPF Drug Failure As Galecto Therapy Suffers Mid-Stage Flop
Firm To Focus On Liver After Lung Miss
Galecto’s decision to discontinue its idiopathic pulmonary fibrosis candidate after disappointing Phase IIb results represents the latest in a number of mid/late-stage failures to treat the disease.
